Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Cipla Ltd. Share Price
Day's Range
Day's Range
Low
₹1,300.10
High
₹1,350.00
Price Summary
| Previous Close | ₹1,304.90 |
|---|---|
| Day's Range | ₹1,300.10 - ₹1,350.00 |
| Open | ₹1,347.00 |
| 52 Week Range | ₹1,165.70 - ₹1,673.00 |
| Volume | 14,28,197 |
| Market Cap | ₹0.11 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 18,818.37 |
|---|---|
| Market Cap (₹ in Mn) | 0.11 |
| Dividend Yield(%) | 1.23 |
| Price/Earning (TTM) | 23.18 |
| TTM EPS (₹) | 56.28 |
| P/E Ratio | 22.08 |
| Book Value(₹) | 3.14 |
| PAT Margin (%) | 14.29 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 23.64 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 70729.7 | 165743.4 |
| Expenses | N/A | N/A |
| PBT | 19069.6 | 49469.7 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 15745.9 | 40772.5 |
About Cipla Ltd.
| Founded | 1935 |
|---|---|
| Managing Director | Achin Gupta |
| NSE Symbol | CIPLA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,49,251.48 | 1,872.40 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,242.24 | 6,728.70 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,951.96 | 4,512.30 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,16,191.66 | 8,085.00 | 6,677.50 - 6,677.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,811.05 | 1,282.15 | 1,138.50 - 1,138.50 |
| Cipla Ltd. | 1,05,391.40 | 1,304.70 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,02,674.68 | 2,249.70 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,937.63 | 2,456.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,01,003.24 | 1,040.85 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 96,261.37 | 956.65 | 835.50 - 835.50 |
No Records Found
Latest News
Cipla informs about disclosure
Pursuant to the provisions of Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, Cipla has informed that the Cipla USA Inc., wholly owned subsidiary of the Company in USA (referred as ‘Cipla’) has received final approval from the United States Food and Drug Administration (‘USFDA’) for the Abbreviated New Drug Application (‘ANDA’) submitted for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, the first AB rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline. Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise induced bronchospasm in patients aged four years and older. The product is expected to be launched in H1 of FY 2026-27 in the United States of America. A press release dated 23rd April 2026 is also enclosed.
Solara Active Pharma Sciences informs about analyst meet
Solara Active Pharma Sciences has informed that the Company has scheduled a conference call with analysts/ investors to discuss Company’s audited financial results for the quarter and financial year ended March 31, 2026 on Friday, May 15, 2026 at 03:00 pm (IST). Analysts / Investors Conference Call details are enclosed. Further, the above information will also be available on the website of the Company: https://solara.co.in/investor-relations/schedule-of-investors-meet-and-investors-presentations.
The above information is a part of company’s filings submitted to BSE.
Sai Life Sciences informs about earnings conference call
Beryl Drugs informs about outcome of EGM
Eris Lifesciences informs about allotment of equity shares
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Cipla Ltd. is ₹1,304.90 as of 2026-05-11.
The market capitalisation of Cipla Ltd. is ₹105,391.40 as of 2026-05-11.
The 1-year return of Cipla Ltd. is 0.00% as of 2026-05-11.
The P/E ratio of Cipla Ltd. is 22.08 as of 2026-05-12.
The 52-week high and low of Cipla Ltd. are ₹1,673.00 and ₹1,165.70, respectively, as of 2026-05-11.
People Also Ask
Cipla operates across India, North America, Africa, Europe, and emerging markets. Its business includes branded and generic formulations, APIs, and consumer healthcare. Revenue is geographically diversified, with India and North America as key contributors. Cipla maintains a broad product portfolio supported by manufacturing facilities across multiple regions.
Key evaluation factors include Cipla's leadership in therapeutic portfolios, new product launches, EBITDA and margin trends, R&D pipeline, regulatory approvals, manufacturing compliance, and innovations in biosimilars and complex therapies.
Cipla’s portfolio includes respiratory, cardiology, central nervous system, oncology, anti-retroviral, urology, and anti-infective medicines. Operations primarily focus on small-molecule formulations and generics. Advanced therapies such as CAR-T or mRNA remain at early research or exploratory stages, not commercial operations.
Performance drivers include pharmaceutical pricing regulations, new product launches, clinical trial success rates, regulatory approvals (e.g., USFDA), competitive pressures, healthcare spending, API cost changes, manufacturing utilization, and the demand for specialty therapies.
Cipla operates across prescription pharmaceuticals, generic medicines, consumer healthcare products, and API manufacturing. These segments support its presence in both regulated and emerging markets through branded, unbranded, and over-the-counter offerings.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
